Gsa Capital Partners LLP Durect Corp Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	BUY	$0.38 - $0.64 $5,828 - $9,816	15,338 New	15,338 $7,000
Q4 2021 Feb 14, 2022	SELL	$0.9 - $1.31 $402,458 - $585,800	-447,176 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$1.21 - $1.61 $63,447 - $84,421	52,436 Added 13.28%	447,176 $572,000
Q2 2021 Aug 05, 2021	BUY	$1.6 - $2.02 $476,948 - $602,147	298,093 Added 308.43%	394,740 $643,000
Q1 2021 May 10, 2021	BUY	$1.86 - $2.87 $28,945 - $44,662	15,562 Added 19.19%	96,647 $191,000
Q4 2020 Feb 03, 2021	SELL	$1.65 - $2.43 $94,822 - $139,647	-57,468 Reduced 41.48%	81,085 $168,000
Q3 2020 Nov 06, 2020	BUY	$1.6 - $2.35 $221,684 - $325,599	138,553 New	138,553 $237,000

593K

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $173M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.